The Health Care sector as a whole closed the day down 0.9% versus the S&P 500, which was down 1.7%. Laggards within the Health Care sector included XTL Biopharmaceuticals ( XTLB), down 2.1%, American Shared Hospital Services ( AMS), down 5.7%, USMD Holdings ( USMD), down 1.5%, Tianyin Pharmaceutical ( TPI), down 9.9% and VBI Vaccines ( VBIV), down 2.4%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today:

Novo Nordisk A/S ( NVO) is one of the companies that pushed the Health Care sector lower today. Novo Nordisk A/S was down $1.66 (2.9%) to $54.97 on average volume. Throughout the day, 1,292,540 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1,315,600 shares. The stock ranged in price between $54.93-$56.50 after having opened the day at $56.13 as compared to the previous trading day's close of $56.63.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $155.3 billion and is part of the drugs industry. Shares are up 33.8% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 1 rates it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, solid stock price performance and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from TheStreet Ratings analysis on NVO go as follows:

  • The revenue growth came in higher than the industry average of 6.8%. Since the same quarter one year prior, revenues slightly increased by 6.1%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Pharmaceuticals industry average. The net income increased by 1.8% when compared to the same quarter one year prior, going from $1,278.47 million to $1,301.18 million.
  • Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 27.47% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, NVO should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • NOVO NORDISK A/S's earnings per share improvement from the most recent quarter was slightly positive. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, NOVO NORDISK A/S reported lower earnings of $1.64 versus $1.73 in the prior year. This year, the market expects an improvement in earnings ($1.95 versus $1.64).

You can view the full analysis from the report here: Novo Nordisk A/S Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, VBI Vaccines ( VBIV) was down $0.06 (2.4%) to $2.45 on light volume. Throughout the day, 258 shares of VBI Vaccines exchanged hands as compared to its average daily volume of 4,800 shares. The stock ranged in price between $2.43-$2.45 after having opened the day at $2.43 as compared to the previous trading day's close of $2.51.

VBI Vaccines has a market cap of $51.3 million and is part of the drugs industry. Shares are down 24.6% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates VBI Vaccines a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

XTL Biopharmaceuticals ( XTLB) was another company that pushed the Health Care sector lower today. XTL Biopharmaceuticals was down $0.04 (2.1%) to $1.82 on average volume. Throughout the day, 5,204 shares of XTL Biopharmaceuticals exchanged hands as compared to its average daily volume of 3,800 shares. The stock ranged in price between $1.82-$1.86 after having opened the day at $1.86 as compared to the previous trading day's close of $1.86.

XTL Biopharmaceuticals has a market cap of $25.3 million and is part of the drugs industry. Shares are down 6.1% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates XTL Biopharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.